Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices

Prevention and Treatment of Thrombosis in Pediatric and Congenital Heart Disease

“…All patients in this study were placed on aspirin 5 mg·kg −1 ·d −1 for 6 months after the procedure. There appears to be a higher incidence of device-related thrombotic complications reported in adults series, 657,660 although these typically also include patients with closure of the PFO after a history of cryptogenic stroke, a population very different from children with simple atrial septal defects.…”

“…Subacute thrombus formation on the device has been a very rare complication reported for every device used for this purpose. [655][656][657][658][659][660][661] In the larger series using multiple devices that have been published, the incidence of device thrombosis is particularly low or nonexistent. 656,659,662,663 The study by Chessa et al 663 reports only 1 device thrombotic complication among 417 patients, and this patent was an adult.…”

“…657,660,664 Often, aspirin therapy is initiated 1 to several days before device implantation. In higher-risk patients such as those with a history of stroke, inherited thrombophilic disorders should be excluded before device implantation so that antithrombotic prophylaxis can be adapted accordingly.…”

Efetividade da prótese de Amplatzer™ para fechamento percutâneo do defeito do septo interatrial tipo Ostium Secundum

“…From the 101 patients included in the study, there were no deaths, cardiac perforations or other serious complications during the hospital phase, which is consistent with the reports in literature 19,20 . During the late evolution, currently at 12.81 ± 8.41 months, no cases of thrombi, embolization or endocarditis related to the device have been recorded even though these complications have been reported in literature [21][22][23] . The Amplatzer ® prothesis has proven to be a safe and effective device and currently can be considered an alternative to surgical treatment for selected patients.…”

Left Atrial Thrombus on Atrial Septal Defect Closure Device as a Source of Cerebral Emboli 3 Years After Implantation

“…Other reports document that most frequent neurological events occur within the first 12 months postimplantation. 1,2 The incidence of thrombus formation ranges from 2.5% to 27%. 3 Risk factors for late thrombus generation are the type of device used, atrial fibrillation, incomplete neoendothelialization of the surface of the device, insufficient antithrombotic therapy, and unknown hypercoagulation disorders including aspirin resistance.…”